Budget Impact Analysis of Cerebrolysin In The Treatment of Acute Ischemic Stroke of Moderate and Severe Degrees of Severity In The Russian Federation

Abstract

A69932.5% oncology, 17.5% auto-immune, 15% cardiovascular, 10% neurology/mental health, 5% infectious, 5% diabetes, and 15% other. Modeling techniques included discrete event simulation (12%), individual state-transition (15%) and most commonly state transition with tracking states. In most cases treatment sequencing was modeled to reflect clinical practice or clinical trial design. Other reasons included assessing where in a treatment sequence the new treatment belongs or evaluating the addition of more efficacious treatment options to the current treatment sequence. Efficacy inputs were generally based on trials that considered a single intervention and not a treatment sequence. Efficacy was commonly assumed to be the same regardless of line of therapy. Disease-related costs and utilities were mostly determined by disease status or its related events, and only seldomly by line of therapy. ConClusions: Capturing treatment sequences in economic models is important for informing reimbursement, policy and clinical decisions. Key considerations for determining how to best model sequences include: the number of treatment options, patient heterogeneity, key outcome events and event risk (time-varying or constant). A key challenge to model treatment sequences is the scarcity of the clinical data as clinical trials do not commonly study sequences. PRM95 Budget IMPact analysIs of ceReBRolysIn In the tReatMent of acute IscheMIc stRoke of ModeRate and seveRe degRees of seveRIty In the RussIan fedeRatIon

Role and Impact of Cerebrolysin for Ischemic Stroke Care

“…Kulikov and Abdrashitova et al have also been developing a complementary budget impact analysis (BIA) since 2015, which showed that Cerebrolysin has lower direct costs associated with medical care (inpatient and outpatient care, pharmacotherapy, emergency care and neurorehabilitation) and indirect costs (loss of productivity caused by sick leave, disability, and death). The costs incurred by stroke patients included in the Cerebrolysin group were reduced by EUR 1314 compared to the cost incurred by patients receiving standard therapy (EUR 7552) [ 56 ]. Walter et al showed that, in patients diagnosed with acute ischemic hemispheric stroke and treated with a combination of alteplase and Cerebrolysin, lower costs were reported (EUR 61,468.67) compared with patients receiving only alteplase.…”

“…While existing studies are scarce, there is a signal that Cerebrolysin is probably cost-effective, with the potential to reduce the economic burden on national budgets, both as standard treatments in patients with different levels of severity [ 55 , 56 ] or in combination with another pharmacological therapy (i.e., alteplase) [ 57 ] in countries with different types of health insurance [ 58 , 59 ].…”